The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation for dexmedetomidine (Dexdor), intended for sedation of adult intensive care unit (ICU) patients. The drug is claimed to allow more flexibility in the ICU setting for patients who do not require deep sedation and reduces the time for extubation compared with the standard of care.